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Pharmacogenomics:
Privacy in the Era of Personalized Medicine
Berrie Rebecca Goldman*
I.
¶1

¶2

INTRODUCTION

Pharmacogenomics is defined as “the use of associations between the effects of
drugs and genetic markers to develop genetic tests that can be used to fine-tune patient
diagnosis and treatment.”1 Researchers in the field of pharmacogenomics study genes
that produce drug-metabolizing enzymes in the body.2 Utilizing an individual’s genetic
profile in prescribing medications for various diseases will prevent unwanted side-effects
and allow drugs to work more efficiently.3 Pharmacogenomics requires the analysis of an
individual’s genetic information and the comparison of that genetic information, along
with reactions to specific drugs, to the information and reactions of others to determine
which drugs most effectively treat a given disease or condition.4 Although
pharmacogenomics is not yet widely used, this technology is likely to someday change
the way physicians practice medicine and the expectations of patients in seeking
treatment. Pharmacogenomics may not only benefit patients by improving physicians’
ability to more accurately provide treatment for diseases and illnesses, but this new
technology may potentially affect patients negatively by risking the individual’s right to
privacy.
The issue of privacy arises as a result of the inherently personal nature of each
individual’s genetic makeup.5 Some people may be reluctant to share this information
with physicians and medical researchers, fearing that they or their family members will
be discriminated against by insurers if they test positive for a genetic disease.6

* Berrie Goldman is a 2006 Juris Doctor candidate at Northwestern University School of Law. She
received her Bachelor of Arts degree in Biomedical Physics from California State University, Northridge,
and her Bachelor of Arts degree in History and English from the University of California, Los Angeles.
1
STUART M. BROWN, ESSENTIALS OF MEDICAL G ENOMICS 253 (2003). Pharmacogenetics, a parallel
field, involves the study of how genes affect the way people respond to drugs. The difference between
pharmacogenomics and pharmacogenetics is slight. Some scientists consider these two fields to be
equivalent, and the terms “pharmacogenomics” and “pharmacogenetics” are sometimes used
interchangeably. LEON SHARGEL ET AL., A PPLIED BIOPHARMACEUTICS & PHARMACOKINETICS 355 (2005).
2
SHARGEL, supra note 1.
3
BROWN, supra note 1.
4
See B. Michael Silber, Pharmacogenomics, Biomarkers, and the Promise of Personalized Medicine, in
PHARMACOGENOMICS 14 (Werner Kalow et. al. eds., 2001).
5
LAURINDA BEEBE HARMAN, ETHICAL CHALLENGES IN THE MANAGEMENT OF H EALTH INFORMATION
275 (2001).
6
See, e.g., id. at 274.
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Each individual has genetic markers, which serve as points of reference.7 These
markers are DNA or protein sequences that are located on a specific region of a
chromosome.8 The developing technology behind pharmacogenomics utilizes these
genetic markers to evaluate how drugs will react in an individual with a specific genetic
profile.9 Pharmacogenomics seeks to determine variations in drug responses by
monitoring genetic changes (alterations in genotype) or physical changes (alterations in
phenotype) in individuals and groups of patients in order to determine the most efficient
and least adverse treatment for disease.10
Pharmacogenomics, as a way of enabling physicians to better treat their patients,
inherently involves comparison and analysis of a large number of genetic profiles.11 In
order to best evaluate which course of treatment to follow, and more specifically which
drug will work best for a patient’s condition, the physician must be able to evaluate other
patients’ responses to treatment options or drugs available for that condition. To provide
the most comprehensive access to genetic profiles, there must be a database containing
that information which physicians can access to determine the likelihood of adverse drug
reactions, side-effects, and efficacy.12 Disclosure of this type of personal information
inevitably leads to privacy issues, as individuals are concerned about sharing their genetic
profiles with the general population.13
This new method of cataloguing and disseminating genetic information is likely to
increase the privacy concerns already associated with genetic research and genetic
testing.14 Several studies have shown concern among United States citizens regarding
discrimination and loss of privacy as a result of sharing their genetic information, and
many cite these concerns as reasons for not participating in medical research studies.15
Pharmacogenomics requires the examination of large numbers of genetic profiles for
success, but individuals will be reluctant to participate unless measures are taken to
ensure confidentiality and restrict the possibility of discriminatory uses of genetic
information.16
This comment will first set forth the technology of pharmacogenomics and its
future applicability to medical treatment. Second, it will propose a solution to the privacy
issues resulting from the development of a pharmacogenomics database. This comment

7

LELAND H. HARTWELL ET AL., GENETICS: FROM GENES TO G ENOMES 113 (2000).
Patricia A. Peyser & Trudy L. Burns, Approaches to Quantify the Genetic Component of and Identify
Genes for Complex Traits, in HUMAN GENOME EPIDEMIOLOGY: A SCIENTIFIC FOUNDATION FOR USING
GENETIC INFORMATION TO I MPROVE H EALTH AND PREVENT DISEASE 43 (Muin J. Khoury et al. eds., 2004).
9
BROWN, supra note 1, at 185-86.
10
SHARGEL, supra note 1, at 360.
11
See Silber, supra note 4.
12
Id.
13
Id.; see also HARMAN, supra note 5.
14
See HARMAN, supra note 5.
15
A 1995 Harris Poll found that “86% of those surveyed were concerned that insurers and employers
might use genetic information against them.” In addition to discrimination in insurance and the workplace,
the survey respondents expressed concern regarding the confidentiality of genetic information used for
research purposes. In 1997, one-third of the women invited to participate in a study of gene mutations
leading to breast cancer declined participation, citing fear of discrimination and loss of confidentiality. Id.
at 275.
16
See id. at 276.
8
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seeks to create a template for federal legislation protecting an individual’s right to
privacy in light of the development of pharmacogenomics technology.
The technological development of pharmacogenomics, examined in Part II,
requires a database to compare and catalog genetic profiles of individuals suffering from
various conditions and undergoing treatment for those conditions.17 Establishing a
database poses issues of confidentiality and privacy, as an individual’s information is
made available to the public, or at least to specific classes of professionals.18 The Health
Insurance Portability and Accountability Act (“HIPAA”) is the current manifestation of
federal protection of patient privacy rights in the United States,19 but this legislation may
not be enough to protect individuals with the creation of a pharmacogenomics database
containing genetic profiles. Part III analyzes the inadequacies of HIPAA in light of the
development of pharmacogenomics and increased usage of genetic databases. Part IV
will discuss how federal law may be tailored to balance patient privacy and the
dissemination of information for the public good. This comment proposes, as a primary
solution to concerns about genetic privacy, federal legislation that expands the scope of
HIPAA to specifically protect information compiled in a pharmacogenomics database, in
addition to providing incentives for patients to contribute to the public welfare by sharing
their genetic profiles.
II.

BACKGROUND - PHARMACOGENOMICS: WHAT IS IT AND HOW DOES IT WORK?
A. History of Pharmacogenomics

¶8

¶9

Pharmacogenomics has been around in some form since the 1930s.20 In 1902,
Archibald Garrod first asserted the hypothesis that genetic variations could cause adverse
biological reactions when chemical substances were ingested.21 He also suggested that
enzymes22 were responsible for detoxifying foreign substances, and that some people do
not have the ability to eliminate certain foreign substances from the body because they
lack enzymes required to break down these materials.23
The first pharmacogenetic study took place in 1932, when the inability to taste a
chemical compound known as phenylthiocarbamide was linked to an autosomal recessive
17

See Silber, supra note 4.
These classes of professionals include physicians and researchers, and may also include insurance
companies and employers. See infra Part IV.c for a discussion of who should have access to a database
created to support pharmacogenomics.
19
Health Insurance Portability and Accountability Act, Pub. L. No. 104-191, 110 Stat. 1936 (1996).
20
David L. Veenstra, The Interface Between Epidemiology and Pharmacogenomics, in HUMAN
GENOME EPIDEMIOLOGY: A SCIENTIFIC FOUNDATION FOR USING GENETIC INFORMATION TO IMPROVE
HEALTH AND PREVENT DISEASE, supra note 8, at 234.
21
Laviero Mancinelli et al., Pharmacogenomics: The Promise of Personalized Medicine, 2 AAPS J. 1, 3
(2000), available at http://www.aapspharmsci.org/articles/ps0201/ps020104/ps020104.pdf. Garrod was a
British physician working at St. Bartholomew’s Hospital in London during the late 19th and early 20th
centuries and is best known for demonstrating that the genetic disorder alkaptonuria results from the
recessive allele of an autosomal gene, which he called an “inborn error of metabolism.” H ARTWELL, supra
note 7, at 201.
22
An enzyme is defined as a protein within a living organism that increases the rate of speed of a
chemical reaction, without being used up during the reaction. KENNETH R. MILLER & JOSEPH LEVINE,
BIOLOGY 75 (2000).
23
Mancinelli, supra note 21.
18
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trait.24 An autosome is a chromosome that does not participate in sex determination,25 and
therefore refers to all the cells in the body except for sperm and eggs. Recessive traits are
described as follows: each person has two genes that code for a particular trait — one is
inherited from the mother and one is inherited from the father.26 If a person inherits two
different alternative forms of a gene, called alleles, the trait that is expressed physically as
a phenotype is the dominant trait, while the one not expressed is a recessive trait.27
Examples of recessive traits include hitchhikers thumb and blue eyes.
¶10
In the 1932 study, participants with two recessive alleles were unable to produce a
particular enzyme that allowed them to taste the phenylthiocarbamide chemical.28 This
determination that the inability to taste was linked to an autosomal recessive trait
demonstrated that certain chemicals react differently depending on genetic
predispositions.29
¶11
In the 1940s and 1950s, scientists first began to note “variable drug responses” in
people taking various preventive medications.30 Drug reactions based on inherited traits
were first recorded during World War II, when some soldiers developed anemia after
receiving doses of the anti-malarial drug primaquine.31 Later studies confirmed that the
anemia was caused by a genetic deficiency of the glucose-6-phosphate dehydrogenase
enzyme.32 Similar reactions to succinlcholine and isoniazid were studied, and revealed
that deficiencies in enzymes led to an inability to metabolize those drugs.33 After
studying adverse drug reactions to primaquine, succinlcholine, and isoniazid, Arno
Moltulsky34 proposed in 1957 that inherited traits may not only lead to adverse drug
reactions, but may also affect whether the drugs actually work.35
¶12
In recent decades, further progress has been made in isolating genetic variations in
major drug-metabolizing enzymes, including cytochrome P450.36 Scientists first began
to study cytochrome P450 when some patients experienced a severe decline in blood
pressure while taking debrisoquin, an anti-hypertensive drug. The study revealed that
these patients had two recessive alleles for the enzyme, resulting in an inability to
24

Id.
BROWN, supra note 1, at 238.
26
U.S. National Library of Medicine, National Institutes of Health, Department of Health & Human
Services, Help Me Understand Genetics 11 (February 25, 2005), available at
http://ghr.nlm.nih.gov/dynamicImages/understandGenetics.pdf.
27
See id. at 51-52; HARTWELL, supra note 7, at 17, 19.
28
Mancinelli, supra note 21.
29
Id.
30
The studies performed evaluated individuals taking isoniazid (to prevent tuberculosis), succinlcholine
(a muscle relaxant), and the anti-malaria drug primaquine. See Veenstra, supra note 20.
31
Mancinelli, supra note 21.
32
Id. The United States Army determined that approximately 10% of African Americans have the
polymorphic allele of glucose-6-phosphate dehydrogenase, leading to the deficiency causing anemia.
BROWN, supra note 1, at 186.
33
Veenstra, supra note 20. The studies revealed that reactions to succinlcholine resulted from a
deficiency in the N-acetyl transferase enzyme, while reactions to isoniazid resulted from a deficiency in the
pseudocholinesterase enzyme.
34
Dr. Motulsky is currently a senior faculty member at the University of Washington, and is continuing
his research in human genetics. UW Genome Sciences Faculty,
http://www.gs.washington.edu/faculty/motulsky.htm (last visited Nov. 1, 2005).
35
Mancinelli, supra note 21.
36
Cytochrome P450 is also referred to as CYP2D6. Veenstra, supra note 20; Mancielli, supra note 21.
25
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metabolize the drug.37 Approximately ten percent of the population metabolizes
cytochrome P450 poorly, experiencing adverse effects and reduced drug uptake when
they take drugs in the family of chemicals metabolized by the enzyme.38 The evaluation
of cytochrome P450 has led to the identification and characterization of many other drugmetabolizing enzymes.39
¶13
Although pharmacogenomics continues to be a burgeoning field of technology, it is
unclear where this new technology will ultimately lead. Currently, research in
pharmacogenomics is primarily focused on preventing adverse drug reactions through the
analysis of the relationship between drug-metabolizing enzymes and the chemical
compounds that those enzymes break down.40 In the future, pharmacogenomics may also
be used to determine which receptors are best equipped to transport particular chemical
compounds into the cell for the purpose of treating a disease or condition.41 Such an
application would allow greater “personalization” of medicine by tailoring drugs to an
individual’s genetic profile.42 Although evaluating receptor participation in drug uptake
is a promising area of research, it is likely that research in the near future will continue to
focus on the evaluation of polymorphisms43 in drug-metabolizing enzymes.44
B. Example of Pharmacogenomics Applicability: Birth Control Pills
¶14

The research carried out by Garrod, Moltulsky, and others illustrates the
importance of genetic factors in determining which drugs will work most effectively and
which will cause adverse reactions.45 However, pharmacogenomics can also aid people
without diseases or enzyme deficiencies. The potential negative effects of oral
contraceptives, provides such an example: women who take birth control pills are
generally young, healthy individuals looking to prevent pregnancy or regulate hormones
for other reasons.46 Although taken by healthy individuals, birth control pills may cause
severe side-effects including blood clots and stroke, which could lead to death.47
¶15
The increasing use of pharmacogenomics will enable physicians to identify risk
factors in a woman’s genetic profile, which may be examined in conjunction with
37

Veenstra, supra note 20.
SHARGEL, supra note 1, at 361-363.
39
Veenstra, supra note 20.
40
SHARGEL, supra note 1, at 360.
41
For an in-depth discussion of the use of receptors in pharmacogenomics, see Wendell W. Weber,
Pharmacogenetics — Receptors, in PHARMACOGENOMICS, supra note 4, at 51.
42
Veenstra, supra note 20.
43
A polymorphism refers to a change in a nucleotide base at a given position on the genome, “when the
frequency of the most common base at that position is [greater than] 99%.” BROWN, supra note 1, at 103.
44
Lars Noah, The Coming Pharmacogenomics Revolution: Tailoring Drugs to Fit Patients’ Genetic
Profiles, 43 JURIMETRICS J. 1, 9 (2002).
45
See Veenstra, supra note 20, at 235.
46
See Jan Vandenbroucke, et. al., Oral Contraceptives and the Risk of Venous Thrombosis, 344 NEW
ENG. J. MED. 1527, 1531-32 (2001).
47
Recent studies have indicated that the risk of blood clots, also known as venous thrombosis, increases
three to six times for women using oral contraceptives over the risk to those who do not use oral
contraceptives. Id. at 1527. Litigation against both physicians and pharmaceutical companies has resulted.
See Brochu v. Ortho Pharmaceutical Corp., 642 F.2d 652 (1st Cir. 1981); Spensieri v. Lasky, 258 A.D.2d
754 (N.Y. 1999); MacDonald v. Ortho Pharmaceutical Corp., 475 N.E.2d 65 (Mass. 1985).
38
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environmental factors to determine whether the use of birth control pills is likely to result
in potentially severe side effects.48 Research in this area has already begun. Scientists
have recently uncovered a genetic mutation, called Factor V Leiden, that increases a
woman’s risk of blood clots, especially when paired with oral contraceptives.49 Factor V
Leiden is a mutation of the Factor V gene, a gene that codes for a glycoprotein circulating
in the blood.50 This mutation is the most common inherited blood-clotting disorder in the
United States, affecting 5% of Caucasians and 1.2% of African-Americans.51 DNA tests
can determine whether an individual is homozygous or heterozygous for the Factor V
Leiden mutation,52 thus increasing her chances of developing blood clots.53 By using this
genetic information, physicians prescribing oral contraceptives may be able to reduce
their patients’ risk of adverse drug reactions like blood clots and stroke.54
C. Method to the Madness: The Technology Behind Pharmacogenomics
¶16

Understanding the scientific processes underlying the technology of
pharmacogenomics requires a short cell biology lesson. Each living organism has a
unique genetic profile comprised of genes that code for the production of proteins.55
Proteins known to affect drug metabolism fall into three categories: (1) proteins that
degrade or activate chemical compounds; (2) proteins that interact with a target molecule
to prevent drugs from binding to a receptor; or (3) proteins that regulate metabolic
pathways that affect drug function.56
¶17
Some proteins themselves act as receptors, and therefore receive chemical signals
from outside the cell.57 These proteins transport molecules into and out of cells, thereby
regulating which materials are allowed to enter the cell.58 Receptors, by virtue of their
gate-keeping function, determine which drugs can enter the cell and fight disease.59
48

See Vandenbroucke, supra note 48, at 1532.
Jan P. Vandenbroucke et al., Factor V Leiden, Oral Contraceptives, and Deep Vein Thrombosis, in
HUMAN G ENOME EPIDEMIOLOGY: A SCIENTIFIC FOUNDATION FOR USING GENETIC INFORMATION TO
IMPROVE H EALTH AND PREVENT DISEASE, supra note 8, at 322.
50
Id. at 324-325.
51
MedicineNet.com, http://www.medterms.com/script/main/art.asp?articlekey=25022 (last visited Oct.
24, 2005). See also Vandenbroucke, supra note 51, at 326 (prevalence of Factor V Leiden is approximately
5% in Caucasians worldwide, but is virtually absent in African and Asian populations).
52
An individual is homozygous for a gene if that individual possesses two identical copies of each gene
coding for an expressed trait. An individual has a heterozygous genotype when that person has two
different forms of a gene that code for an expressed trait. HARTWELL, supra note 7, at 19. The presence of
the mutation, either in homozygous (two copies of the mutation) or heterozygous (one copy of the
mutation) form, increases the probability that a woman will develop blood clots while taking oral
contraceptives. See Vandenbroucke, supra note 51, at 326.
53
Vandenbroucke, supra note 51, at 326.
54
See Vandenbroucke, supra note 48, at 1532.
55
HARTWELL, supra note 7, at G-10.
56
BROWN, supra note 1, at 186. The drug-metabolizing enzymes discussed supra Part II.a fall into the
third protein category.
57
HARTWELL, supra note 7, at 2.
58
See A RTHUR M. LESK, INTRODUCTION TO PROTEIN SCIENCE: ARCHITECTURE, FUNCTION AND
GENOMICS 25 (2004).
59
The genetic sequence that codes for a protein also codes for its shape. Shape is an important feature
of a protein, as it is this shape that determines how the protein will function. HARTWELL, supra note 7, at
203.
49
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Receptors on the surface of cells vary depending on genotype, as DNA determines the
characteristics of proteins.60 Because of this variance, people react differently to different
medications, as one person’s receptors may allow a chemical into the cell while another
person’s receptors may prevent the cell from absorbing that drug.61
¶18
In addition to determining which chemicals to allow into the cell, some proteins
serve to alter the shape of drug molecules, effectively turning them “on.”62 Evaluating
which genotypes allow chemicals to be turned on, and which keep the drugs “off,” will
allow physicians to determine the medications that will work for their patients.63
Geneticists can now identify single genetic markers in an individual’s genetic profile that
code for drug-interaction genes, which will ultimately increase physicians’ ability to
prescribe the appropriate medication without the risk of side-effects or the possibility of
failed treatment.64
D. Pharmacogenomics Versus Genetic Testing
¶19

Pharmacogenomics is considerably different from genetic testing because it
requires an evaluation of a person’s entire genetic profile, not just the presence or
absence of single genetic markers.65 Genetic testing was previously conducted under the
theory that most diseases were monogenic, meaning that one gene caused each disorder.66
Now, the general belief has shifted toward the concept of polygenic disorders, where
multiple mutated genes contribute to a single disorder.67 Due to this shift in theory,
genetic testing now involves analyses of multiple portions of the genome, but still does
not require analysis of the complete genetic profile.68 Although both pharmacogenomics
and genetic testing involve comparing genes to determine the likelihood of future disease,
only pharmacogenomics compares whole genetic profiles to evaluate drug efficacy and
potential adverse reactions.69
¶20
The success of the pharmacogenomics technology therefore depends on compiling
complete genetic profiles that will allow physicians to compare thousands of single
nucleotide polymorphisms (“SNPs”) 70 from one individual with those of another
individual.71 A comparison of these markers across the entire genome will enable
physicians and researchers to “screen groups of patients receiving a specific drug and
then correlate good and poor drug efficacy and the occurrence of specific side effects
60

Id. at 2.
See LESK, supra note 60.
62
National Institutes of Health, Medicines for You, available at
http://publications.nigms.nih.gov/medsforyou/MedsForYou.pdf.
63
Id.
64
BROWN, supra note 1, at 186.
65
Id.
66
SHARGEL, supra note 1, at 360.
67
Id.
68
See BROWN, supra note 1, at 187-88.
69
Silber, supra note 4, at 24.
70
Single Nucleotide Polymorphisms, also known as SNPs, are defined as “single base pair mutations
that appear at frequencies above 1% in the population.” BROWN, supra note 1, at 257. In plain English, an
SNP is one change in the sequence of amino acids that comprise a strand of DNA. SNPs are frequently
used to identify genes related to disease. Peyser, supra note 8, at 44.
71
BROWN, supra note 1, at 187.
61
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with individual SNP markers.”72 As a result of these comparisons, physicians and
researchers may determine which genetic markers influence adverse drug reactions and
which genetic markers increase drug efficacy.73
III.
¶21

ANALYSIS

In the near future, pharmacogenomics is likely to become the standard used by
physicians to prescribe medications to their patients.74 Prior to the full development of
this technology, it is important to consider its privacy implications and what should be
done to protect the confidentiality of each patient’s genetic information.75 The sections
below evaluate the need for a database containing genetic information, the current
statutory system for genetic information privacy in the United States, and how the current
system should be revised and expanded in order to protect confidentiality of genetic
information as pharmacogenomics progresses.
A. The Pharmacogenomics Database

¶22

Pharmacogenomics cannot succeed unless a system is developed where a large
number of genetic profiles and individual responses to drugs may be compared to
evaluate drug efficacy and potential adverse reactions.76 The most efficient way to
evaluate and compare genetic profiles and individual drug response is to develop a
national database containing this information.77 However, the development of such a
database presents significant issues of privacy and confidentiality. Many patients are
concerned that their information may be used without their consent and they will be
discriminated against in areas of insurance and employment.78
¶23
The key to a beneficial pharmacogenomics program is the development of a
database, linking data obtained in the lab with data obtained from patients.79 Such a
database would enable scientists to compare large numbers of patient profiles and access
information gleaned from laboratory research.80 Although pharmacogenomics has great
potential to revolutionize medicine, if genetic information is kept private, the technology
will not succeed.81
¶24
The current manifestation of a pharmacogenomics database exists in the
Pharmacogenomics Knowledge Base (“PharmGKB”), and is funded by the National

72

Id.
Id.
74
See Darrell L. Ellsworth & Christopher J. O’Donnell, Emerging Genomic Technologies and Analytic
Methods for Population- and Clinic-Based Research, in HUMAN G ENOME EPIDEMIOLOGY: A SCIENTIFIC
FOUNDATION FOR USING GENETIC INFORMATION TO IMPROVE HEALTH AND PREVENT DISEASE, supra note
8, at 33.
75
Silber, supra note 4.
76
Silber, supra note 4.
77
Id.
78
See HARMAN, supra note 5, at 274-75; see also supra text accompanying note 15.
79
Silber, supra note 4.
80
Id.
81
Id.
73

90

Vol. 4:1]

Berrie Rebecca Goldman

Institute of General Medical Science, a branch of the National Institutes of Health.82 The
database is based on a project entitled the Pharmacogenomics Research Network83 and
represents a synthesis of studies evaluating the functions of proteins, identifying
polymorphisms, and assessing the relationship of genetic variants to clinical drug
responses. 84 The database includes information on a subject’s health, including history of
disease, physical/physiologic characteristics,85 the drugs taken and the response to those
drugs, as well as DNA sequences that may play a role in drug metabolism.86 PharmGKB
currently contains data on 597 genes, sixty drugs, and eighteen diseases.87 PharmGKB
contains no identifying personal information, and consists of only partial DNA sequences
as opposed to full genetic profiles.88
¶25
PharmGKB does not contain full genetic profiles, however, and will not be
sufficient as pharmacogenomics becomes essential for treating diseases and conditions.
Additionally, the fact that PharmGKB does not contain any identifying information could
pose difficulties. Although anonymity safeguards privacy, including some form of
identifying information would allow for notification. Notification may be necessary, or
at least desired, as the database grows and increases the number of genetic markers
known to affect drug metabolism. Individuals may want to know if the drugs they are
taking may be replaced by more effective treatment options. In order for patients to
receive the benefits of the database, there must be a way to notify them if information
contained in the database suggests the drugs they are taking may be replaced by more
effective treatment options.
B. Privacy Concerns
¶26

Developing a database containing genetic profiles poses a significant problem —
privacy. Patients may not want to share their genetic profiles for fear that they may be
discriminated against by insurance companies, employers, and others.89 Similarly,
making genetic information available to the public, or at least to a specific segment of the
public, namely physicians, marks a decline in patient autonomy.90 Patients will not be
82

Press Release, National Institutes of Health, NIH Renews Network Focused On How Genes Influence
Drug Responses (Sept. 28, 2005) available at
http://www.nigms.nih.gov/News/Results/20050928PGRN.htm (last visited Oct. 24, 2005).
83
The NIH recently announced plans to expand the Pharmacogenomics Research Network over the next
five years, and anticipates spending approximately $150 million on the project. Id.
84
BROWN, supra note 1, at 190.
85
Physical characteristics available in the Pharmacogenomics Knowledge Base include height, weight,
blood pressure, and other relevant characteristics. Access to the Pharmacogenomics Knowledge Base may
be found at http://www.pharmgkb.org.
86
BROWN, supra note 1, at 190.
87
These numbers are current as of October 10, 2005. However, the number of genes, drugs, and
diseases with primary information available in the PharmGKB database is rapidly expanding. The numbers
in each category have almost doubled over the past nine months. Pharmacogenomics Knowledge Base, at
http://www.pharmgkb.org/ (last visited October 24, 2005).
88
BROWN, supra note 1, at 191.
89
See HARMAN, supra note 5, at 274-75.
90
Patient autonomy is a substantive principle of social justice, stating that “each person is in control of
his own person, including his body and mind.” This principle is often compared with the principle of
beneficence, where “what is best for each person should be accomplished.” These two principles may
come into conflict when an individual wants something for himself that others believe is not best for him.
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able to decide who has access to their personal information if it is freely accessible in a
public database.91
There are many other potential public costs of a national genetic database.
Individuals will not consider sharing their information if the opportunity cost is too high.
It may be difficult to persuade individuals to share their genetic information if they are
concerned about the availability of insurance or employment when their profile reveals
the potential for genetic disease.92 Additionally, individuals, especially older generations,
may not clearly understand the technology and therefore may be less likely to participate
in such a system.
One potential comfort to patients is that privacy in pharmacogenomics should not
be as much of a concern as privacy in genetic testing.93 Because genetic testing involves
identification of potential disease-causing biomarkers, individuals may be understandably
concerned about sharing this extremely private information with others.94
Pharmacogenomics, however, focuses on responses to medication.95 This focus on
medication, as opposed to a focus on potential development of diseases, should decrease
apprehension regarding the sharing of information, as it is less likely to lead to
discrimination in insurance or in the workplace.
Nonetheless, the privacy concern raises the issue of whether individuals would be
willing to share their genetic profiles with others to benefit the public. If a significant
percentage of the population were to donate their profiles to a pharmacogenomics
database, the likelihood that researchers could successfully link drug responses to specific
genetic characteristics would increase exponentially.96 On the other hand, if concerns
about discrimination and misunderstanding of technology restrict sharing of genetic
information, the pharmacogenomics database will ultimately be less efficient.97
Greater participation in the database will ultimately lead to an increased
opportunity for research to identify and isolate polymorphisms affecting drug
metabolism.98 People should be willing to share their information because they and their
family members will reap the future benefits of a database indicating which drugs will
cause adverse reactions and which drugs will work most effectively for their conditions.

FURROW ET AL., BIOETHICS: HEALTH CARE LAW AND ETHICS 229 (2001). This issue is likely to arise in
pharmacogenomics when someone declines the use of his profile for privacy reasons, even though it would
be in his best interest and the best interest of society to contribute to research that will increase the
effectiveness of drugs.
91
The National Institutes of Health and various research groups have continued to push for public
access to genetic information in recent years in order to improve the efficient dissemination of information
and advancement of science. For a discussion of public versus private databases, see Adam D. Marks and
Karen K. Steinberg, The Ethics of Access to Online Genetic Databases: Private or Public?, 3 A M. J.
PHARMACOGENOMICS 207 (2002).
92
See HARMAN, supra note 5.
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Silber, supra note 4, at 24.
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See HARMAN, supra note 5, at 274-75.
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Silber, supra note 4, at 24.
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See id. at 14.
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See Henry T. Greely, Genotype Discrimination: The Complex Case for Some Legislative Protection,
149 U. PA. L. REV. 1483, 1501 (2001).
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See Silber, supra note 4.
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C. The Current Privacy Standard: HIPAA
¶31

The Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) is the
current federal health information privacy law in the United States.99 HIPAA protects the
confidentiality of a patient’s medical information by limiting its collection, use, and
disclosure.100
¶32
Section 701(b)(1)(B) addresses genetic information. It states that “[g]enetic
information shall not be treated as a condition described in subsection (a)(1) in the
absence of a diagnosis of the condition related to such information.”101 Therefore,
insurance companies are prohibited from refusing to enroll an individual or charging
higher premiums based on information gleaned from that individual’s genetic profile.102
Under HIPAA § 701(b)(1), insurance companies may only utilize genetic information if
there has already been a confirmed diagnosis of disease.103
¶33
Although the provisions contained in HIPAA that place strict standards on
healthcare providers and insurance companies work well for genetic testing, these
standards will not be strong enough to address privacy concerns once a
pharmacogenomics database is developed. Pharmacogenomics will require the use of
genetic information before a condition has developed because researchers in this field
evaluate the interactions of enzymes produced by genes, and not diseases resulting from
the presence or absence of such genetic markers.104 In almost all cases, there will be an
“absence of a diagnosis of the condition related”105 when researchers are using the
genetic information to determine which drug is most effective and poses the least risk.
Based on these considerations, it is necessary to amend HIPAA to explicitly include
genetic databases.
IV.
¶34

PROPOSED SOLUTION: RECONCILING THE NEED FOR A GENETIC DATABASE WITH AN
INDIVIDUAL’S RIGHT TO PRIVACY

With the continuing concern over genetic privacy and potential discrimination,
increased protections must be implemented in order to encourage individuals to
99

Pub. L. No. 104-191, 110 Stat. 1936 (1996).
Jeffrey N. Gibbs, State Regulation of Pharmaceutical Clinical Trials, 59 FOOD & DRUG L.J. 265, 266
(2004).
101
Section 701(a) provides that insurance companies may exclude coverage for a preexisting condition
only under the following circumstances:
(1) such exclusion relates to a condition (whether physical or mental), regardless of the cause of
the condition, for which medical advice, diagnosis, care, or treatment was recommended or
received within the 6-month period ending on the enrollment date;
(2) such exclusion extends for a period of not more than 12 months (or 18 months in the case of
a late enrollee) after the enrollment date; and
(3) the period of any such preexisting condition exclusion is reduced by the aggregate of the
periods of creditable coverage (if any, as defined in subsection (c)(1)) applicable to the
participant or beneficiary as of the enrollment date.
§ 701(a)(1-3), 110 Stat. at 1939.
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Id.; § 701(b)(1)(B), 110 Stat. at 1940.
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See Silber, supra note 4, at 24.
105
Pub. L. No. 104-191 § 701(b)(1)(B), 110 Stat. at 1940.
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contribute their genetic information to a pharmacogenomics database. 106 As discussed in
Part III.a, comparisons of large numbers of genetic profiles are essential to the success of
pharmacogenomics technology.107 Without some assurance that genetic information will
not be used for discriminatory purposes, patients will be understandably reluctant to
participate in the collection of data for a pharmacogenomics database. 108 This section
will discuss how the current law may be improved to address genetic privacy concerns in
pharmacogenomics.
A. Expanding HIPAA: The Need for a New Federal Law (or at least an addition to the
old law)
¶35

In order to protect an individual’s right to privacy once the pharmacogenomics
database becomes a reality, Congress must pass a federal law to supplement HIPAA. The
law must be federal — although state law could adequately protect individuals, the
database itself must be available nationally in order to improve its efficiency.109
Uniformity is also necessary to ensure that all individuals contributing to the database are
afforded the same protections and benefits under a federal law.110
¶36
Establishing a new federal law to protect privacy concerns involving the
pharmacogenomics database poses the question of whether this federal law should
preempt state law. HIPAA currently does not preempt state law where the state law
provides greater privacy protections.111 Allowing more stringent privacy protections
provided by state law may limit the amount of available information in a
pharmacogenomics database, thereby decreasing the benefit to all who utilize the system.
Therefore, such a provision may also reduce the efficiency of the system by limiting the
number of people who contribute their profiles to the database. A pharmacogenomics
database would be most effective and provide the most material to evaluate drug efficacy
and reactions if this proposed federal law preempted state law.112
B. The Privacy Rule
¶37

When HIPAA was passed in 1996, the statute required the Secretary of Health and
Human Services to design standards for its implementation.113 In compliance with the

106

See Greely, supra note 100, at 1500-01.
See Silber, supra note 4, at 14.
108
See Greely, supra note 100, at 1499-1502.
109
Under HIPAA, states are currently allowed to implement more stringent standards supplementing
federal law to protect genetic information without the possibility of preemption. HIPAA IN PRACTICE: THE
HEALTH INFORMATION MANAGER’S PERSPECTIVE 8 (American Health Information Management
Association ed., 2004).
110
One of the reasons for implementing HIPAA was to ensure uniformity among the states in protecting
the confidentiality of health information. Gina Marie Stevens, A Brief Summary of the HIPAA Medical
Privacy Rule, CRS REPORT FOR CONGRESS RS20934 (2003). Similarly, any addition to current law should
represent a federal standard in order to continue uniformity of health information protection throughout the
United States.
111
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112
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113
Pub. L. No. 104-191 § 262, 110 Stat. at 1938.
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Administrative Simplification provisions of the Act,114 the Secretary published the
Standards for Privacy of Individually Identifiable Health Information on December 28,
2000.115 These standards, more commonly referred to as the Privacy Rule, were finalized
on August 14, 2002, and required health plan and health care provider compliance by
April 13, 2003.116 The Privacy Rule states that HIPAA applies to group health plans
covering more than fifty individuals and all health care providers, regardless of size, who
transmit health information electronically.117
¶38
The Privacy Rule allows health care providers to disclose information about their
patients as long as there is a justification for doing so.118 The Privacy Rule “protects all
‘individually identifiable health information’119 held or transmitted by a covered entity or
its business associate, in any form or media, whether electronic, paper or oral,”120 which
presumably includes genetic information.
¶39
Although the Privacy Rule offers strong protections against the disclosure of
information, the Rule also provides for situations in which disclosure is permissible.121
Health care providers may disclose information for the “public good” without
authorization by the patient.122 Under the public good exception, medical information
may be disclosed without the patient’s consent to a public health authority for purposes of
controlling or monitoring disease, or to government agencies such as the Food and Drug
Administration (“FDA”) for evaluation of adverse drug reactions.123 It is this element of
unauthorized disclosure that poses difficulties for the level of privacy needed for a
successful pharmacogenomics database.
114

Id.
UNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICES O FFICE OF CIVIL RIGHTS PRIVACY
BRIEF: SUMMARY OF THE HIPPA PRIVACY RULE 2 (May 2003), available at
http://www.hhs.gov/ocr/privacysummary.pdf.
116
Id. at 2, 18.
117
Id. at 2.
118
CAROLYN P. HARTLEY, MLA, CHP & EDWARD D. JONES III, HIPAA PLAIN & SIMPLE: A
COMPLIANCE GUIDE FOR HEALTH CARE PROFESSIONALS 58 (2004).
119
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mental health or condition of an individual,” or relates to the provision of or payment for health care
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(2005).
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Hartley, supra note 121, at 91.
123
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¶40

The pharmacogenomics database is likely to fall under the “public good” exception
to disclosure, thereby reducing an individual’s ability to exclude her information from the
database. 124 The pharmacogenomics database may qualify as a “public good” under any
number of circumstances allowing disclosure without the individual’s consent, including
disclosure to a public-health authority or the FDA, or disclosure for research purposes.125
¶41
Because the pharmacogenomics database will be compiled for the good of the
public in preventing adverse reactions and increasing drug efficacy, it is necessary to
require informed consent of individuals who wish to include their profiles in the database.
As the law stands now, the “public good” exception to confidentiality would allow
researchers and compilers to obtain information that individuals desire to keep private.126
Therefore, a provision governing the pharmacogenomics database and requiring informed
consent must be included in a new federal law in order to protect the individual’s right to
privacy.
C. Access to Information Under the Proposed Law
¶42

The current privacy law in the United States, as governed by HIPAA and related
provisions promulgated under HIPAA such as the Privacy Rule, must be expanded to
specifically address genetic information contained in databases like those required for the
success of pharmacogenomics technology. Once these provisions are expanded to protect
against unauthorized disclosure of genetic information, access to a pharmacogenomics
database must be granted not only to physicians and researchers, but also to insurance
companies. This would encourage growth and development of the system while also
providing tangible financial benefits to the general public.
¶43
With the development of a new pharmacogenomics database, it is important to
determine who will have access to such a database, and codify these restrictions in new
legislation. Physicians and researchers would unequivocally require access to the
pharmacogenomics database. Physicians must access the database to aid in determining
which drugs will cause the fewest side-effects and most effectively treat their patients’
conditions. Researchers must also have the ability to access the database in order to
make comparisons of genetic profiles to determine which genes affect drug-metabolizing
enzymes.127
¶44
Although it seems clear that physicians and researchers must have access to the
pharmacogenomics database, other groups may want access as well. Insurance
companies are the most problematic of these groups, as discrimination by insurance
agencies is one of the most foreseeable improper uses of an individual’s genetic
information.128
¶45
The argument for not granting access to insurance companies is based on the idea
that insurance companies could utilize genetic information to deny coverage or to raise
124

For research purposes, a health care provider may release health information without the consent of
the patient as long as an institutional review board or privacy board approves a waiver of authorization.
There are no other requirements. JANE M. SULLIVAN, HIPAA: A PRACTICAL GUIDE TO THE PRIVACY AND
SECURITY OF HEALTH DATA 45 (2004).
125
45 C.F.R. § 164.512 (i-j).
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See SULLIVAN, supra note 127.
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See Barbara P. Fuller & Kathy Hudson, Genetic Information, in HARMAN, supra note 5, at 275.
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premiums.129 However, even HIPAA prohibits insurance companies from using genetic
information to evaluate coverage limitations and premiums, unless the patient has been
diagnosed with a disease or condition.130 The proposed federal statute should follow
HIPAA’s example in strongly protecting an individual’s right to keep genetic information
private, especially when applied to the pharmacogenomics database.
¶46
As long the proposed expansion of HIPAA is applied to information contained in
the pharmacogenomics database, there are multiple advantages in allowing insurance
companies to gain access to such information. First, allowing access to such a database
will ultimately result in lower premium costs for consumers by greatly diminishing the
incentive for insurance companies to engage in reverse engineering. Second, providing
such access to insurance companies will benefit those companies financially, providing
an incentive for the insurance industry to make financial contributions in support of the
pharmacogenomics database. Support from the insurance industry should ultimately
cause the database to expand more quickly, resulting in tangible benefits to patients
sooner rather than later. However, these advantages will only occur if the insurance
industry is forbidden from using genetic information to discriminate where the patient has
not yet developed a disease or condition.
1.

Reducing Consumer Costs by Preventing Reverse Engineering of Genetic
Information

¶47

The potential new federal law governing the pharmacogenomics database must
include access for insurance companies. If access by insurance companies were
restricted, it would likely lead to a sort of “reverse engineering.” Reverse engineering
typically appears in the context of trade secrets.131 An individual may purchase a product
on the open market, then take it apart to see how it works, thus potentially revealing the
trade secrets of the manufacturer.132 Reverse engineering may also apply in the context
of the pharmacogenomics database. Insurance companies may employ physicians or
geneticists to determine the presence or absence of specific genes in an individual’s
genetic profile based on the treatment prescribed by that individual’s physician for a
given condition. The insurance companies will waste money trying to determine, which
of their customers have the potential for developing costly conditions. Doing so may
allow the insurance company to skirt the HIPAA provision preventing disclosure of
genetic information, thereby providing an avenue for higher premiums or a denial of
coverage.
¶48
Although HIPAA explicitly states that premiums cannot be increased due to nondiagnosed conditions,133 insurance companies may be able to determine genetic markers
for specific diseases anyway through reverse engineering. Because of this, insurance
companies should have full access to the pharmacogenomics database under the new law,
which should retain HIPAA’s guard against the misuse of genetic information and
129
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expand it to specifically include the pharmacogenomics database. Since HIPAA
explicitly states that premiums cannot be increased due to non-diagnosed conditions,134
people will not be penalized financially for the possibility that they will develop a genetic
disease in the future.
2.

Financial Incentives for Insurance Companies Translate into Benefits for the
Public

¶49

The development of the pharmacogenomics database will not only help the public,
but will also financially benefit the insurance industry. The database, once it is fullyoperational, will reduce insurance companies’ expenditures. As researchers determine
with more accuracy which genes or gene combinations affect drug metabolism,
physicians will be able to provide treatment options with more certainty.135 Experimental
treatments and drugs, which are customarily more expensive, will be used less frequently,
as patients will receive effective initial treatment of their condition. Therefore, insurance
companies will not be required to pay for multiple prescriptions or various expensive
procedures in an effort to uncover a successful treatment for disease.
¶50
Drug companies are already realizing a decrease in expenditures as a result of
pharmacogenomics.136 During the early stages of clinical trials, drug companies are
comparing genetic profiles of patients in order to determine which individuals react
positively to the new drug.137 In the later stages of clinical trials, patients are prescreened to eliminate those individuals that may experience side effects or otherwise
react poorly to the drug.138 As a result, new drugs may become available that would
otherwise be declined due to side effects or lack of effectiveness for a large percentage of
the population.139 Similarly, insurance companies will ultimately receive a financial
benefit because the insured will only receive a particular medication if that individual’s
genetic profile indicates a high degree of efficacy and a low risk of negative side
effects.140
¶51
Due to the strong financial benefit to insurance companies, it is less likely that
insurance companies will take advantage of the pharmacogenomics database by using it
to discriminate against their clients. It is possible that the insurance industry may even
contribute financially to the initial development of the database, or by providing
incentives to those covered under their plans who donate their profiles. Since the
insurance industry will not benefit from the database until it is well-established, that
industry has a strong incentive to encourage the development of the pharmacogenomics
database.

134
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V.
¶52

¶53

¶54

¶55

¶56

CONCLUSION

Pharmacogenomics will forever alter the way that physicians, patients, and the
general public perceive genetic information. In the near future, the expansion of
pharmacogenomics will result in patients’ contribution of their genetic profiles to a
database, enabling both themselves and the public to reap the benefits of a system that
will most effectively distribute pharmaceuticals for treatment of all types of diseases and
conditions. Individuals will want to use the system in order to reduce the risk of
unwanted side-effects and adverse drug reactions, as well as to increase the effectiveness
of medications necessary to treat disease or relieve symptoms.
The current manifestation of a pharmacogenomics database, PharmGKB, will
probably not be sufficient to provide adequate comparisons of genetic profiles because
(quick synopsis). The new database, or modification to the existing PharmGKB
database, must include entire genetic profiles, as most conditions and enzyme
deficiencies reducing drug metabolism are now thought to be based in more than one
gene.141
It remains to be seen how the logistics of developing a new pharmacogenomics
database will work out. The National Institutes of Health is be the most likely candidate
to run the database, as it has experience in the area of managing genetic databases with
the Human Genome Project. Other issues that need to be addressed include funding for
the project, creation of software, and whether to require licensing of software.
New legislation must be passed to enhance the privacy laws already in place. This
legislation must be federal and must include specific provisions for databases containing
genetic material, as well as for collection, use, and distribution of information derived
from an individual’s genetic profile.142 Databases of genetic material need not be
protected more than other types of health information,143 but genetic information
contained in databases must be expressly protected by federal legislation in order to
ensure privacy rights. New legislation should also include provisions requiring informed
consent, as information collected for the pharmacogenomics database may be susceptible
to the public good exception to the existing HIPAA Privacy Rule. As individuals must
have the ability to decide whether to include their genetic information in the
pharmacogenomics database, informed consent must be required under the new law to
prevent disclosure without the individual’s consent.
The change in legislation must precede the changing technology in order to create
the most efficient and beneficial pharmacogenomics system. A new law governing the
pharmacogenomics database need not be dramatically different from current privacy laws
in the United States. The scope of current law simply must be expanded to include
patients’ rights to prevent their information from being publicly available on such a
database, and to require informed consent under all circumstances. The law should also
include a provision encouraging individuals to register their genetic profiles on the
database, as the greater the number of people who contribute, the more likely that the
database will be a successful medical tool.
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